NASDAQ$CGON
CG Oncology Inc · Q2 2025 earnings
Q2 2025 earnings ·
Briefing
CGON Q2 2025 — n/d revenue, 30.00 EPS
The par value of the common stock and preferred stock was not adjusted as a result of the reverse stock split. CG Oncology Inc reported Q2 2025 results. Diluted EPS came in at $30.00. Net income of $75.9M. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Diluted EPS: $30.00.
- Net income: $75.9M.
- Operating income: $49K.
Headline financials
Revenue & EPS history
CG Oncology Inc · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports · overlaid with Q2 2025
+0.6%
Avg return
Earnings day
+1.8%
Avg return
5 days after
+5.6%
Avg return
30 days after
63%
5 / 8 earnings
Positive
+8.6%
Q3 2025
Best reaction
-7.4%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.6% | +6.9% | -22.5% | |
| Q4 2025 | +4.8% | +9.7% | +15.2% | |
| Q3 2025 | +8.6% | +12.8% | +8.4% | |
| Q2 2025 | +2.1% | +8.8% | +35.8% | |
| Q1 2025 | -3.9% | +1.1% | +5.3% | |
| Q3 2024 | -6.8% | -17.1% | -27.3% | |
| Q2 2024 | +7.0% | +7.9% | +22.5% | |
| Q1 2024 | -7.4% | -15.8% | +7.6% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro